JD CCEP - AtriCure Chief Officer
| ATRC Stock | USD 36.17 0.38 1.06% |
Executive
JD CCEP is Chief Officer of AtriCure
| Age | 53 |
| Address | 7555 Innovation Way, Mason, OH, United States, 45040 |
| Phone | 513 755 4100 |
| Web | https://www.atricure.com |
AtriCure Management Efficiency
The company has return on total asset (ROA) of (0.0351) % which means that it has lost $0.0351 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0839) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.05. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jonathan Ngau | LeMaitre Vascular | 50 | |
| Juan Serna | AngioDynamics | N/A | |
| Daniel Esq | CONMED | 60 | |
| Scott Centea | AngioDynamics | 45 | |
| Harold Tamayo | Axogen Inc | N/A | |
| Maik Helmers | LeMaitre Vascular | 50 | |
| Laura Piccinini | AngioDynamics | 55 | |
| Marna BronfenMoore | AngioDynamics | 57 | |
| Saleem Cheeks | AngioDynamics | N/A | |
| Hollie Foust | CONMED | N/A | |
| Kimberly Lockwood | CONMED | N/A | |
| David Hissong | LeMaitre Vascular | N/A | |
| John Ferrell | CONMED | 56 | |
| Richard Glaze | CONMED | 58 | |
| Sarah Oliker | CONMED | 43 | |
| Maria Martinez | Axogen Inc | 56 | |
| Todd Puckett | Axogen Inc | N/A | |
| Jens Kemp | Axogen Inc | N/A | |
| CFA CPA | Axogen Inc | 50 | |
| Michael Donovan | Axogen Inc | 59 | |
| Doris Quackenbush | Axogen Inc | N/A | |
Management Performance
| Return On Equity | -0.0839 | ||||
| Return On Asset | -0.0351 |
AtriCure Leadership Team
Elected by the shareholders, the AtriCure's board of directors comprises two types of representatives: AtriCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AtriCure. The board's role is to monitor AtriCure's management team and ensure that shareholders' interests are well served. AtriCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AtriCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Deborah Yount, Chief Officer | ||
| Valerie StorchWillhaus, Vice Communications | ||
| Michael Carrel, CEO and President and Director | ||
| Tonya SPHR, VP HR | ||
| Vinayak Doraiswamy, Chief Officer | ||
| Amalio MD, Ex Officer | ||
| JD CCEP, Chief Officer | ||
| Angela CPA, Chief Officer | ||
| Salvatore JD, Chief Officer | ||
| Justin Noznesky, Senior Vice President Marketing and Business Development | ||
| CCEP CCEP, Chief Officer | ||
| Douglas Seith, Chief Officer |
AtriCure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AtriCure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0839 | ||||
| Return On Asset | -0.0351 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 48.75 M | ||||
| Shares Owned By Insiders | 3.18 % | ||||
| Shares Owned By Institutions | 96.82 % | ||||
| Number Of Shares Shorted | 1.67 M | ||||
| Price To Earning | 33.47 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AtriCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AtriCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atricure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atricure Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share 9.564 | Quarterly Revenue Growth 0.179 | Return On Assets (0.04) | Return On Equity (0.08) |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.